Primary human cytomegalovirus (CMV) infection during pregnancy is one of the most common causes of congenital malformation [1]. In all, approximately 0.2-2.5% neonates worldwide are affected by congenital CMV infection [2]. Congenital CMV infection occurs via the intrauterine transmission of the virus. About 90% of the newborns infected during gestation are reported to be asymptomatic at birth, while others show varying degree of complications from hepatosplenomegaly, petechiae, and thrombocytopenia to more profound symptoms, including mental retardation, motor 557 557 557
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Soyeon Seo, YoungSook Cho, and Joonseok Park function disturbance, and hearing loss [3] . Even among the newborns without apparent clinical manifestations at birth, about 5-15% can develop delayed sequelae [3] .
Because most infected pregnant women present only nonspecific symptoms, it is necessary to develop laboratory methods to diagnose primary CMV infection [4] . The usefulness of conducting serologic examination of maternal serum for CMV infection has been limited by the overlapping features between primary and non-primary infection, which does not cause severe congenital malformation and hence does not warrant specific intervention [5] [6] [7] . Therefore, it is important to distinguish primary infection from non-primary infection to provide targeted prenatal care to women who are at a high risk of transmitting CMV infection to their offspring. Recent advances in diagnostic methods have led to the development of reliable CMV IgG avidity tests that can detect primary CMV infection with a strong specificity of about 98% without compromising sensitivity [8] . This has also enabled the development of an algorithmic screening approach that incorporates CMV IgG, IgM, and IgG avidity tests to identify women who are at high risk of intrauterine transmission of the virus [4] .
Using these serologic tests, it has become possible to easily obtain vital information on primary CMV infection. In Korea, although a few reports on CMV seroprevalence are available, there are no reliable data on the incidence of primary CMV infection during pregnancy [9, 10] . Hence, we aimed to estimate the frequency of primary CMV infection across pregnant Korean women using a recently developed CMV IgG avidity test.
MATERIALS AND METHODS

Materials
During a 2-month period, 744 pregnant Korean women at 10-19 weeks of gestation were consecutively enrolled for CMV serologic testing. Their serum samples were prospectively screened for CMV from November to December 2008.
These women were visiting the primary women' s clinic (Motaean Women' s Hospital and Dana Women Clinic) for rou-tine antenatal care. All the subjects provided a written informed consent. The mean age of the women enrolled in this study was 21.9±7.2 yr (mean±2SD).
Serum was separated from whole blood specimens obtained from the women, within 4 hr from collection. Serum specimens were maintained at 2-8℃ until serological assays were performed. Serological assays were not delayed for more than 10 days after blood collection. zone results were treated in the same manner as the reactive results as previously described [8] .
Methods
An automated IgG avidity assay (ARCHITECT CMV IgG
Avidity; Abbott Laboratories, Abbott Park, IL, USA) was performed to distinguish between primary and non-primary CMV infections for cases that showed reactivity both with CMV IgG and IgM, provided adequate amount of sera was available. The CMV IgG avidity assay comprised two 2-step immunoassays performed using chemiluminescence technology. For each specimen, one aliquot of the sample was pretreated with CMV lysate that resulted in the selective binding and removal of the high-avidity antibody, while another aliquot was pretreated with the buffer without the 
Statistical analysis
Student' s t test was used for comparing between CMV
IgM-seropositive and CMV IgM-seronegative women in terms of age, gestational age at the time of serologic testing, body weight, and concentration of CMV IgG. The differences were analyzed with MedCalc (MedCalc Software; Mariakerke, Belgium), and a P value of less than 0.05 was regarded as statistically significant.
Although ARCHITECT CMV IgM is a qualitative assay, a signal to cutoff ratio can be obtained for this assay. For evaluating the probability of false positivity of the assay, a negative d value was calculated as logarithmic population means of signal to cutoff ratios divided by the logarithmic standard deviation of the signal to cutoff ratios [11] . The results for the women who showed grey zone reactivity on CMV IgM were not used for calculating the negative d value, because these women were treated as seropositive in this study.
RESULTS
Of the 744 pregnant women included in this study, 730 (98.1%) were seropositive for CMV IgG. 
DISCUSSION
Primary CMV infection during pregnancy is known to be associated with the development of congenital malformation with a 15-25% probability [3] . Although the risk involved in recurrent maternal CMV infections cannot be neglected, the possibility of serious sequelae such as neurologic manifestations is thought to be very low [12] . Therefore, the risk of congenital CMV infection was thought to be closely related to the history of the infection in mothers, thereby resulting in the existence of antibodies against CMV before pregnancy [1] . In this study, 98.1% of the pregnant women had CMV IgG. Seroprevalence of CMV IgM was estimated to be 1.7%, provided the grey zone was included.
Compared to the results of previous studies, seroprevalence of CMV antibody across pregnant Korean women has not changed significantly: it was 98.9% in 1984 and 96.0% in 1992 [9, 10] . Seroprevalence of CMV IgG obtained in this study was similar to that in Japan (94%), but was higher than that in the United States (50-88%), the UK (56-60%),
and Italy (70%) [13] .
On the basis of the recommended cut off value, a nega- Table 1 . Characteristics of the women with positive results both on cytomegalovirus IgG and IgM serological tests culated owing to the limited number of positive specimens.
Thus far, there have been no data on the frequency of primary CMV infection during pregnancy in Korea due to the lack of an accessible method to identify primary CMV infection. PCR of CMV isolated from the amniotic fluid could be a feasible approach. However, its usefulness was shown to be significantly limited by a low diagnostic sensitivity of 30-45% prior to 21 weeks of gestation and its innate invasiveness [4] .
Presently, the CMV IgG avidity assay seems to be one of the most accessible tools to differentiate primary from nonprimary CMV infection with substantial reliability in patients with CMV IgG-and IgM-positive sera. A clinical study on 31 pregnant women with recent primary CMV infection revealed that both the currently available automated CMV IgG avidity assays, including the ARCHITECT CMV IgG Avidity assay, could identify all the pregnant women whose CMV IgG was seroconverted within the past 4 months [8] .
More specifically, in their study, ARCHITECT CMV IgG Avidity showed a low level in all the 25 cases whose CMV IgG was converted from negative to positive within the past 4 months but changed to a high level after 40 weeks, implying its applicability to detect primary CMV infection in pregnant women [8] .
Because of the high sensitivity for identifying primary CMV infection, CMV IgG avidity tests have been occasionally used in the past. However, wide ranges of the grey zone (up to 60%) and incorporation of manual steps in the previously available assays hindered their wide acceptance in clinical laboratories [8] . In addition, the interpretation criteria recommended by the manufacturers were not always acceptable for evaluating primary infection [4] . However, the ARCHITECT CMV IgG Avidity has significantly addressed these issues. According to a previously published report, of the 100 patients with non-primary CMV infection, 24%
failed to show high level CMV IgG avidity with a previously available alternative immunoassay, while 98% showed high CMV IgG avidity using ARCHITECT [8] . Because ARCHI-TECT CMV IgG Avidity has a fully automated assay procedure and a narrow grey zone of only 10%, the authors could reliably identify women with primary infection in a time-dependent manner using the unmodified interpretation criteria provided by the manufacturer [8] . In this study, low avidity or grey zone avidity was not observed among the 12 CMV IgG-and IgM-positive pregnant women who were tested by the CMV IgG avidity test. All the women whose samples were tested with CMV IgG avidity were th- 
